Ginkgo Bioworks Holdings, Inc. provided revenue guidance for the year 2022. The company continues to expect total revenue of $460 million - $480 million in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.35 USD | +20.65% |
|
+13.42% | -79.29% |
07-16 | Ginkgo Bioworks Partners With Syngenta Crop Protection for new Biologicals | MT |
07-09 | Goldman Sachs Adjusts Price Target on Ginkgo Bioworks to $0.30 From $0.80, Maintains Sell Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-79.29% | 780M | |
+25.83% | 47.96B | |
+44.76% | 41.47B | |
+0.69% | 42.45B | |
+30.52% | 31.6B | |
+22.30% | 28.63B | |
-6.35% | 28.03B | |
+49.25% | 14.56B | |
+49.18% | 14.14B | |
+3.45% | 12.58B |
- Stock Market
- Equities
- DNA Stock
- News Ginkgo Bioworks Holdings, Inc.
- Ginkgo Bioworks Holdings, Inc. Provides Revenue Guidance for the Year 2022